Revance Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch RVNC and buy or sell other stocks, ETFs, and their options commission-free!About RVNC
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders.
CEONadeem Moiz, MBA, CPA
CEONadeem Moiz, MBA, CPA
Employees—
Employees—
HeadquartersNashville, Tennessee
HeadquartersNashville, Tennessee
Founded1999
Founded1999
Employees—
Employees—
RVNC Key Statistics
Market cap382.87M
Market cap382.87M
Price-Earnings ratio-1.90
Price-Earnings ratio-1.90
Dividend yield—
Dividend yield—
Average volume697.72K
Average volume697.72K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$7.56
52 Week high$7.56
52 Week low$2.30
52 Week low$2.30
Stock Snapshot
The current Revance Therapeutics(RVNC) stock price is $3.65, with a market capitalization of 382.87M. The stock trades at a price-to-earnings (P/E) ratio of -1.90.
On 2025-11-05, Revance Therapeutics(RVNC) stock opened at —, reached a high of —, and a low of —.
Revance Therapeutics(RVNC) shares are trading with a volume of 0, against a daily average of 697.72K.
In the last year, Revance Therapeutics(RVNC) shares hit a 52-week high of $7.56 and a 52-week low of $2.30.
In the last year, Revance Therapeutics(RVNC) shares hit a 52-week high of $7.56 and a 52-week low of $2.30.
People also own
Based on the portfolios of people who own RVNC. This list is generated using Robinhood data, and it’s not a recommendation.